Samson Clinical completes patient recruitment for clinical trial of male-pattern baldness drug
AGA affects up to 80 per cent of men across their lifetime and remains one of the most common and most psychologically challenging forms of hair loss
AGA affects up to 80 per cent of men across their lifetime and remains one of the most common and most psychologically challenging forms of hair loss
The results demonstrated meaningful reductions in the severity of involuntary movements and notable improvements in patient-reported quality of life
Vitiligo, affecting over 90 per cent of patients in its non-segmental form, is characterized by symmetrical white patches on both sides of the body
Anti-microtubule binding region-tau antibody being investigated as a potential disease-modifying therapy to slow or delay progression of disease
No post-injection Delirium/Sedation Syndrome (PDSS) observed through 56 weeks
The safety profile in alopecia areata was generally consistent with that in approved indications, and no new safety signals were identified in this study
The program will offer a structured and immersive learning experience for over 20,000 healthcare professionals across more than 10 cities
LEQSELVI now available for prescription in U.S. nationwide, offering a new option for eligible patients
Review will evaluate effectiveness in treating alcohol withdrawal syndrome and supporting abstinence, as well as measures to mitigate risk of abuse
Subscribe To Our Newsletter & Stay Updated